Univercells is dedicated to increasing the availability of vaccines and biotherapeutics to address global health challenges. We are developing turnkey solutions for a series of critical vaccines and biosimilars to enable affordability in low- and moderate-income countries.
To achieve this, we have developed innovative biomanufacturing processes for viral production (vaccines, gene therapy vectors) and antibodies that utilize automated and closed bioprocessing in smaller footprints than conventional processes of similar scale.
Our scale-X™ single-use fixed-bed bioreactor scales up to 600m² and our NevoLine™ intensified and integrated manufacturing platform provides low-cost, large-scale capacity with low capital and operating costs. In addition to our turnkey projects, scale-X bioreactor and NevoLine platform are commercially available for third party use.